Form 4: Agilon Health CFO Granted 600,000 RSUs

Agilon Health's Chief Financial Officer, Jeffrey A. Schwaneke, was granted 600,000 restricted stock units, vesting over three years starting January 10, 2026.

Summary

• Jeffrey A. Schwaneke, Chief Financial Officer of agilon health, inc. (AGL), was granted 600,000 shares of common stock.
• These shares are restricted stock units (RSUs) with a transaction price of $0, indicating a grant.
• The RSUs are scheduled to vest in three equal installments on each anniversary of January 10, 2026.
• Following this reported transaction, Mr. Schwaneke will beneficially own 1,675,122 shares, which includes these restricted stock units.

Sentiment

Score: 7

Explanation: The grant of a significant number of restricted stock units to a key executive like the CFO is generally viewed positively as it aligns management's long-term interests with those of shareholders and serves as a strong retention tool.

Positives

• The grant of 600,000 restricted stock units to the Chief Financial Officer aligns management's interests with long-term shareholder value.
• The three-year vesting schedule acts as a retention mechanism for a key executive talent.

Negatives

• NA

Risks

• NA

Future Outlook

The grant of restricted stock units with a multi-year vesting schedule suggests a commitment to retaining key executive talent and aligning their incentives with the company's long-term performance and shareholder value creation.

Industry Context

The grant of restricted stock units is a common executive compensation practice in the healthcare technology and services industry, aiming to incentivize long-term performance and retain key leadership within competitive talent markets.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a standard practice across various industries, including healthcare technology, similar to companies like Teladoc Health (TDOC) or Amwell (AMWL), which often use equity grants to align executive interests with shareholder value.
• The three-year vesting schedule is also typical for such grants, providing a balance between immediate incentive and long-term retention, comparable to practices seen at companies like UnitedHealth Group (UNH) or CVS Health (CVS) for their executive equity programs.

Related Party Transactions

• The grant of restricted stock units to the Chief Financial Officer is a form of related party transaction as it involves compensation to an executive.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.
• Management: Strengthens retention and incentivizes long-term commitment to company goals.

Next Steps

• The first installment of restricted stock units is scheduled to vest on January 10, 2027.
• The second installment of restricted stock units is scheduled to vest on January 10, 2028.
• The third and final installment of restricted stock units is scheduled to vest on January 10, 2029.

Key Dates

Recommendation

This Form 4 reports a standard executive compensation event involving the grant of restricted stock units to the Chief Financial Officer. While it signals management retention and alignment with long-term shareholder interests, it does not present new fundamental information that would significantly alter the investment thesis for agilon health, inc. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific compensation disclosure.

Keywords

agilon health, AGL, Form 4, RSU, restricted stock units, executive compensation, Jeffrey A. Schwaneke, CFO, insider transaction